REPLIGEN CORP (RGEN) Stock Fundamental Analysis

NASDAQ:RGEN • US7599161095

134.88 USD
+0.21 (+0.16%)
Last: Feb 25, 2026, 10:56 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

RGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year RGEN was profitable.
  • In the past year RGEN had a positive cash flow from operations.
  • In multiple years RGEN reported negative net income over the last 5 years.
  • RGEN had a positive operating cash flow in 4 of the past 5 years.
RGEN Yearly Net Income VS EBIT VS OCF VS FCFRGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

  • RGEN's Return On Assets of 0.06% is fine compared to the rest of the industry. RGEN outperforms 67.24% of its industry peers.
  • With a decent Return On Equity value of 0.08%, RGEN is doing good in the industry, outperforming 68.97% of the companies in the same industry.
  • RGEN has a Return On Invested Capital of 1.05%. This is in the better half of the industry: RGEN outperforms 60.34% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RGEN is significantly below the industry average of 11.97%.
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROIC 1.05%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
RGEN Yearly ROA, ROE, ROICRGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8

1.3 Margins

  • RGEN has a Profit Margin of 0.25%. This is in the better half of the industry: RGEN outperforms 67.24% of its industry peers.
  • Looking at the Operating Margin, with a value of 6.58%, RGEN is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
  • RGEN's Operating Margin has declined in the last couple of years.
  • RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 58.62% of its industry peers.
  • In the last couple of years the Gross Margin of RGEN has declined.
Industry RankSector Rank
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
RGEN Yearly Profit, Operating, Gross MarginsRGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • RGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGEN Yearly Shares OutstandingRGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
RGEN Yearly Total Debt VS Total AssetsRGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • An Altman-Z score of 6.31 indicates that RGEN is not in any danger for bankruptcy at the moment.
  • RGEN has a better Altman-Z score (6.31) than 89.66% of its industry peers.
  • RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
  • RGEN has a Debt to FCF ratio of 5.05. This is in the better half of the industry: RGEN outperforms 67.24% of its industry peers.
  • RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.26, RGEN perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Altman-Z 6.31
ROIC/WACC0.1
WACC10.43%
RGEN Yearly LT Debt VS Equity VS FCFRGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

  • RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
  • RGEN's Current ratio of 8.36 is amongst the best of the industry. RGEN outperforms 91.38% of its industry peers.
  • A Quick Ratio of 7.14 indicates that RGEN has no problem at all paying its short term obligations.
  • RGEN's Quick ratio of 7.14 is amongst the best of the industry. RGEN outperforms 89.66% of its industry peers.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 7.14
RGEN Yearly Current Assets VS Current LiabilitesRGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.54%, which is quite good.
  • The Earnings Per Share has been growing slightly by 0.60% on average over the past years.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.12%

3.2 Future

  • Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 26.12% on average per year.
  • Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 17.04% on average per year.
EPS Next Y24.26%
EPS Next 2Y25.75%
EPS Next 3Y28.24%
EPS Next 5Y26.12%
Revenue Next Year12.44%
Revenue Next 2Y13.71%
Revenue Next 3Y15.06%
Revenue Next 5Y17.04%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
RGEN Yearly Revenue VS EstimatesRGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
RGEN Yearly EPS VS EstimatesRGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 78.88, the valuation of RGEN can be described as expensive.
  • RGEN's Price/Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 26.98, RGEN is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 63.48, the valuation of RGEN can be described as expensive.
  • RGEN's Price/Forward Earnings ratio is in line with the industry average.
  • RGEN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.01.
Industry RankSector Rank
PE 78.88
Fwd PE 63.48
RGEN Price Earnings VS Forward Price EarningsRGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
  • RGEN's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 71.3
EV/EBITDA 66.41
RGEN Per share dataRGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • RGEN's earnings are expected to grow with 28.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.25
PEG (5Y)132.5
EPS Next 2Y25.75%
EPS Next 3Y28.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for RGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

REPLIGEN CORP

NASDAQ:RGEN (2/25/2026, 10:56:47 AM)

134.88

+0.21 (+0.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)04-27
Inst Owners110.6%
Inst Owner Change-0.01%
Ins Owners0.45%
Ins Owner Change-2.86%
Market Cap7.59B
Revenue(TTM)N/A
Net Income(TTM)1.74M
Analysts81.43
Price Target191.52 (41.99%)
Short Float %7.73%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.29%
PT rev (3m)1.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
Industry RankSector Rank
PE 78.88
Fwd PE 63.48
P/S 10.73
P/FCF 71.3
P/OCF 58.01
P/B 3.64
P/tB 13.21
EV/EBITDA 66.41
EPS(TTM)1.71
EY1.27%
EPS(NY)2.12
Fwd EY1.58%
FCF(TTM)1.89
FCFY1.4%
OCF(TTM)2.33
OCFY1.72%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)3.25
PEG (5Y)132.5
Graham Number37.73
Profitability
Industry RankSector Rank
ROA 0.06%
ROE 0.08%
ROCE 1.67%
ROIC 1.05%
ROICexc 1.43%
ROICexgc 5.46%
OM 6.58%
PM (TTM) 0.25%
GM 51.59%
FCFM 15.04%
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF 5.05
Debt/EBITDA 4.85
Cap/Depr 37.9%
Cap/Sales 3.45%
Interest Coverage 250
Cash Conversion 117.95%
Profit Quality 6126.58%
Current Ratio 8.36
Quick Ratio 7.14
Altman-Z 6.31
F-Score6
WACC10.43%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y24.26%
EPS Next 2Y25.75%
EPS Next 3Y28.24%
EPS Next 5Y26.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%18.12%
Revenue Next Year12.44%
Revenue Next 2Y13.71%
Revenue Next 3Y15.06%
Revenue Next 5Y17.04%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year68.8%
EBIT Next 3Y36.96%
EBIT Next 5Y34.6%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%

REPLIGEN CORP / RGEN FAQ

Can you provide the ChartMill fundamental rating for REPLIGEN CORP?

ChartMill assigns a fundamental rating of 5 / 10 to RGEN.


What is the valuation status for RGEN stock?

ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.


What is the profitability of RGEN stock?

REPLIGEN CORP (RGEN) has a profitability rating of 5 / 10.


What is the financial health of REPLIGEN CORP (RGEN) stock?

The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.


What is the earnings growth outlook for REPLIGEN CORP?

The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 24.26% in the next year.